Alumis, Inc. (ALMS)
23.96
+0.94
(+4.06%)
USD |
NASDAQ |
Aug 25, 16:00
23.96
0.00 (0.00%)
After-Hours: 17:16
Alumis Net Income (Quarterly) : -142.22M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -142.22M |
| March 31, 2026 | -93.05M |
| December 31, 2025 | -92.93M |
| September 30, 2025 | -110.75M |
| June 30, 2025 | 59.32M |
| March 31, 2025 | -98.96M |
| December 31, 2024 | -94.76M |
| Date | Value |
|---|---|
| September 30, 2024 | -93.12M |
| June 30, 2024 | -56.51M |
| March 31, 2024 | -49.85M |
| December 31, 2023 | -39.30M |
| September 30, 2023 | -43.38M |
| June 30, 2023 | -36.29M |
| March 31, 2023 | -36.03M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 42.14M |
| Aclaris Therapeutics, Inc. | -21.50M |
| Crinetics Pharmaceuticals, Inc. | -120.86M |
| Tarsus Pharmaceuticals, Inc. | -18.55M |
| Structure Therapeutics, Inc. | -106.33M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.662M |
| Total Expenses (Quarterly) | 143.88M |
| EPS Diluted (Quarterly) | -1.114 |
| Enterprise Value | 2.494B |
| Gross Profit Margin (Quarterly) | 47.41% |
| Profit Margin (Quarterly) | -8.56K% |
| Earnings Yield | -15.89% |
| Normalized Earnings Yield | -14.61 |